SCHEMBL4187556

SCHEMBL4187556

CCc1ccccc1COC1(S(=O)(=O)NC(=O)OC(C)(C)C)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.43
CA14 Q9ULX7 3/20 0.43
CA1 P00915 2/20 0.43
CA7 P43166 2/20 0.43
NQO2 P16083 1/20 0.36
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.34
CA2 P00918 1/20 0.34
SYK P43405 1/20 0.34
KCNA5 P22460 1/20 0.34
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
GAA P10253 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 1/20 0.33
ATM Q13315 1/20 0.33
CTSL P07711 1/20 0.33
MMP1 P03956 1/20 0.33
MMP13 P45452 1/20 0.33
ADAM17 P78536 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL313082 0.85 CA12 (0.54) CA12CA14CA1CA7CA2
SCHEMBL28827505 0.72 CA12 (0.45) CA12CA14CA1CA7CA2
SCHEMBL8356015 0.71 CA12 (0.43) CA12CA14CA1CA7NQO2
SCHEMBL8011499 0.69 CA12 (0.52) CA12CA14CA1CA7CA2
SCHEMBL4193420 0.68 CA12 (0.47) CA12CA14CA1CA7CA2
SCHEMBL13980716 0.68 POLB (0.50) LMNAPOLBMEN1GAAKMT2A
SCHEMBL29991524 0.68 POLB (0.50) LMNAPOLBMEN1GAAKMT2A
SCHEMBL25156176 0.67 HDAC4 (0.46) CA12CA14CA1CA7LMNA
SCHEMBL30344367 0.67 HDAC4 (0.46) CA12CA14CA1CA7LMNA
SCHEMBL12688182 0.67 CA12 (0.46) CA12CA14CA1CA7ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090047244-A1 MACROCYCLIC SERINE PROTEASE INHIBITORS I IDENIX PHARMACEUTICALS, INC. (US) 2009-02-19 US disclosed
WO-2009014730-A1 MACROCYCLIC SERINE PROTEASE INHIBITORS IDENIX PHARMACEUTICALS, INC. (US) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090047244-A1 MACROCYCLIC SERINE PROTEASE INHIBITORS I SERPINB1, SPINT2, PRSS1 CA12 3636/4885CA14 2640/4885CA1 3683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.